# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in o...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...
Genmab A/S (NASDAQ: GMAB) announced today that it will assume sole responsibility for the continued development and potential ...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.